Connect your AI

ClearPoint Neuro CLPT 2029

2029 at other companies

AbbottABT

——

IAR

Integra LifeSciencesIART

——

MedtronicMDT

——

ITG

Integer HoldingsITGR

——

Globus MedicalGMED

——

Ginkgo BioworksDNA

——

Other financials

Income statement

Revenue$12.1M+42.9%

Gross profit$7.8M+51.1%

Operating income-$8.5M-37.6%

Net income-$9.6M-58.5%

EPS (diluted)-$0.32-45.5%

Balance sheet

Cash & equivalents$36.5M+195%

Total debt$63.6M+1,750%

Total equity$18.8M-5.7%

Total assets$93.4M+211%

Cash flow

Operating cash flow-$8.0M-29.1%

CapEx$645.0K+252%

Free cash flow-$8.6M-35.5%

Valuation

Market cap$538.61M+69.2%

Enterprise value$565.68M+82.9%

P/S13.3×+3.4×

Profitability

Gross margin62.3%+1.1pp

Operating margin-65.2%-1.9pp

Net margin-71.6%+8.8pp

FCF margin-65.7%+269pp

Returns & leverage

Return on equity-149.7%+4,074pp

Debt / equity3.4×+3.2×

Current ratio5.8×+2.3×

Where this comes from

Reported directly by ClearPoint Neuro in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree.

The official record: ClearPoint Neuro’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about ClearPoint Neuro's 2029.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is ClearPoint Neuro's 2029?: ClearPoint Neuro (CLPT) reported 2029 of $1.46M in Q1 2026.